Results 151 to 160 of about 20,527 (318)

Efficacy and safety of dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis: a subanalysis of three clinical trials [PDF]

, 2019
Norito Katoh, Yoko Kataoka, Hidehisa Saeki, Michihiro Hide, Kenji Kabashima, Takafumi Etoh, Atsuyuki Igarashi, Shinichi Imafuku, Makoto Kawashima, Mamitaro Ohtsuki, Hiroyuki Fujita, Kazuhiko Arima, Hiroki Takagi, Z. Chen, Brad Shumel, Marius Ardeleanu   +15 more
openalex   +1 more source

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes, Lian F. van der Gang, Daphne S. Bakker, C. F. den Hartog Jager, Marlies de Graaf, Marjolein S. de Bruin‐Weller, Femke van Wijk, Edward F. Knol   +7 more
wiley   +1 more source

A critical appraisal and implications of the new National Institute for Health and Care Excellence guideline on dupilumab for treating moderate‐to‐severe atopic eczema [PDF]

, 2019
Stephan Weidinger, Christian Apfelbacher
openalex   +1 more source

Evaluation of Small Airways Dysfunction With Dupilumab Using Airway Oscillometry in Uncontrolled Severe Asthma

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 264-266, March 2025.
Kirsten E. Stewart, Chris RuiWen Kuo, Rory Chan, Brian J. Lipworth   +3 more
wiley   +1 more source

Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis

, 2018
Olabola Awosika, Lori Kim, Momina Mazhar, Mónica Rengifo‐Pardo, Alison A Ehrlich   +4 more
openalex   +2 more sources

The utility of dupilumab for use in the pediatric population [PDF]

, 2019
Aakaash Varma, Michael Tassavor, J. Levitt   +2 more
openalex   +1 more source

Dupilumab for the Treatment of Cutaneous Immune‐Related Adverse Events: A Systematic Review

International Journal of Dermatology, EarlyView.
ABSTRACT The emergence of immune checkpoint inhibitors has revolutionized the landscape of cancer treatment in the modern era. However, cutaneous immune‐related adverse events (cirAEs) are common, significantly affecting patients' quality of life and often leading to treatment discontinuation, which may compromise oncological outcomes.
Ioannis‐Alexios Koumprentziotis, Aikaterini Niforou, Antonios Tsimpidakis, Christos Nikolaou, Alexander Stratigos, Vasiliki Nikolaou   +5 more
wiley   +1 more source

Recalcitrant generalized granuloma annulare treated successfully with dupilumab [PDF]

, 2020
Eingun James Song, Joshua Bezecny, Sterling Farrer   +2 more
openalex   +1 more source

Distinct Cytokine Profiles in Chronic Spontaneous Urticaria Refractory to H1‐Antihistamines Compared to Healthy Controls

Clinical &Experimental Allergy, EarlyView.
Young‐Min Ye, Hyun‐Young Lee, Da‐Hye Moon, Kun‐Woo Park, Se‐Min Park   +4 more
wiley   +1 more source

Drug survival analysis of dupilumab and associated predictors in patients with atopic dermatitis in South Korea: single-center, retrospective study

Scientific Reports
Dupilumab is a biologic medication that is used for the treatment of moderate-to-severe atopic dermatitis (AD). Long-term data on dupilumab drug survival in Asia patients with AD are limited.
Tae Woong Seul, Hyun Woo Park, Hyo Yoon Kim, Jung Jin Shin, Sang Wook Son   +4 more
doaj   +1 more source